

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 March 2025 (06.03.2025)



(10) International Publication Number
WO 2025/049521 A2

- (51) **International Patent Classification:**
C07D 403/12 (2006.01) *A61K 31/506* (2006.01)
- (21) **International Application Number:**
PCT/US2024/044106
- (22) **International Filing Date:**
28 August 2024 (28.08.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/579,241 28 August 2023 (28.08.2023) US
63/620,520 12 January 2024 (12.01.2024) US
63/651,602 24 May 2024 (24.05.2024) US
- (71) **Applicant: SYNDAX PHARMACEUTICALS, INC.**
[US/US]; 35 Gatehouse Drive, Building D, Floor 3,
Waltham, Massachusetts 02451 (US).
- (72) **Inventors: MCGEEHAN, Gerard, M.;** 3741 Rose-
mont Pass, Newtown Square, Pennsylvania 19073 (US).
MILLER, William, H.; 132 Chinaberry Lane, Col-
legeville, Pennsylvania 19426 (US). **SAMANTA, Swapan**
Kumar; A-407, Mayflower Grande, Nacharam-Mallapur
Road, Mallapur, Hyderabad 500076 (IN). **REDDY, Virsin-**
ha Venkat; 3-475/84, Surya Nagar, Old Alwal, Hyderabad
500010 (IN). **SINGAM, Naveen Kumar;** Flat No. 154,
Shashank Enclave, Dammaiguda, Hyderabad 500083 (IN).
KULKARNI, Santosh S.; A206, Temple Trees Apartment,
J P Nagar 6th Phase, Kanakapura Main Road, Bangalore
560078 (IN).
- (74) **Agent: ERLACHER, Heidi, A. et al.;** Cooley LLP, 1299
Pennsylvania Avenue, NW, Suite 700, Washington, District
of Columbia 20004 (US).
- (81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

- (84) **Designated States** (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- *as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))*

Published:

- *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*

- (54) **Title:** ARYL ETHER ANALOGS AS INHIBITORS OF THE MENIN-MLL INTERACTION



Formula (I).

(57) **Abstract:** The present disclosure is directed to inhibitors of Formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.

WO 2025/049521 A2